USPTO serial 97501359
BLUEROCK
Reviewed by CopyMark Law Group
Status 734Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- ROSEN, BENJAMIN H
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with BLUEROCK?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $648*
Plus Government fees of $300
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Phillip Barengolts
Phillip Barengolts Pattishall, McAuliffe, Newbury, Hilliard & Geraldson LLP125 S. Wacker DriveSuite 2050Chicago, IL 60606Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Cells for medical or clinical use; genetic material being cells and biological tissue cultures for medical or clinical use; cell therapy and genetic medicine-based pharmaceutical and therapeutic pharmaceutical preparations for the treatment of Parkinson's disease, cancer, cardiovascular disease, ophthalmological diseases, autoimmune disorders, neurological disorders, lysosomal disorders, central nervous system diseases, gastrointestinal disorders, dermatological disorders, inflammatory diseases, metabolic disorders, respiratory diseases, and endocrine diseases; pharmaceutical and therapeutic pharmaceutical preparations in the nature of cells for human use for treating Parkinson's disease, cancer, cardiovascular disease, ophthalmological diseases, autoimmune disorders, neurological disorders, lysosomal disorders, central nervous system diseases, gastrointestinal disorders, dermatological disorders, inflammatory diseases, metabolic disorders, respiratory diseases, and endocrine diseases through cell therapy or gene therapy; cell therapy and genetic medicine-based pharmaceutical preparations for the treatment of Parkinson's disease, cancer, cardiovascular disease, ophthalmological diseases, autoimmune disorders, neurological disorders, lysosomal disorders, central nervous system diseases, gastrointestinal disorders, dermatological disorders, inflammatory diseases, metabolic disorders, respiratory diseases, and endocrine diseases through gene therapy and cell therapy | ACTIVE | — |
| 044 | Medical treatment of Parkinson's disease, cancer, cardiovascular disease, ophthalmological diseases, autoimmune disorders, neurological disorders, lysosomal disorders, central nervous system diseases, gastrointestinal disorders, dermatological disorders, inflammatory diseases, metabolic disorders, respiratory diseases, and endocrine diseases; collection and preservation of human biological tissue, blood and cells for medical diagnostic testing purposes; medical diagnostic testing, monitoring and reporting services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 18, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 17, 2026 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Aug 17, 2026 | NOAC | CORRECTED NOA E-MAILED | — |
| Aug 17, 2026 | DPCC | DIVISIONAL PROCESSING COMPLETE | — |
| Aug 14, 2026 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Apr 21, 2026 | EXT5 | SOU EXTENSION 5 FILED | — |
| Apr 21, 2026 | DRRR | DIVISIONAL REQUEST RECEIVED | — |
| Apr 21, 2026 | ERTD | TEAS REQUEST TO DIVIDE RECEIVED | — |
| Apr 21, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 5, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Nov 4, 2025 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Nov 4, 2025 | EXT4 | SOU EXTENSION 4 FILED | — |
| Nov 4, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 6, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 6, 2025 | EX3G | SOU EXTENSION 3 GRANTED | — |
| May 5, 2025 | EXT3 | SOU EXTENSION 3 FILED | — |
| May 5, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 17, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Dec 17, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 17, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Oct 24, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 24, 2024 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Oct 24, 2024 | EXT2 | SOU EXTENSION 2 FILED | — |
| Oct 24, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 12, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Apr 11, 2024 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Apr 11, 2024 | EXT1 | SOU EXTENSION 1 FILED | — |
| Apr 11, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 14, 2023 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Oct 12, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Oct 12, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 12, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Oct 3, 2023 | WOAG | WITHDRAWAL OF ATTORNEY GRANTED | — |
| Oct 3, 2023 | WOAR | TEAS WITHDRAWAL OF ATTORNEY RECEIVED | — |
| Sep 19, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 19, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 30, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 25, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Aug 25, 2023 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Aug 25, 2023 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Aug 15, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 15, 2023 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Aug 15, 2023 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Aug 15, 2023 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Aug 15, 2023 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jul 31, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 28, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 28, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 28, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 28, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 28, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 27, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 2, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 16, 2022 | NWAP | NEW APPLICATION ENTERED | — |